000306230 001__ 306230
000306230 005__ 20251118110920.0
000306230 0247_ $$2doi$$a10.3389/fonc.2020.614468
000306230 0247_ $$2pmid$$apmid:33585241
000306230 0247_ $$2pmc$$apmc:PMC7873936
000306230 037__ $$aDKFZ-2025-02459
000306230 041__ $$aEnglish
000306230 082__ $$a610
000306230 1001_ $$aBaram, Tamir$$b0
000306230 245__ $$aInflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy.
000306230 260__ $$aLausanne$$bFrontiers Media$$c2020
000306230 3367_ $$2DRIVER$$aarticle
000306230 3367_ $$2DataCite$$aOutput Types/Journal article
000306230 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763460518_1939188$$xReview Article
000306230 3367_ $$2BibTeX$$aARTICLE
000306230 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000306230 3367_ $$00$$2EndNote$$aJournal Article
000306230 500__ $$a#DKFZ-MOST-Ca187#
000306230 520__ $$aCellular heterogeneity poses an immense therapeutic challenge in cancer due to a constant change in tumor cell characteristics, endowing cancer cells with the ability to dynamically shift between states. Intra-tumor heterogeneity is largely driven by cancer cell plasticity, demonstrated by the ability of malignant cells to acquire stemness and epithelial-to-mesenchymal transition (EMT) properties, to develop therapy resistance and to escape dormancy. These different aspects of cancer cell remodeling are driven by intrinsic as well as by extrinsic signals, the latter being dominated by factors of the tumor microenvironment. As part of the tumor milieu, chronic inflammation is generally regarded as a most influential player that supports tumor development and progression. In this review article, we put together recent findings on the roles of inflammatory elements in driving forward key processes of tumor cell plasticity. Using breast cancer as a representative research system, we demonstrate the critical roles played by inflammation-associated myeloid cells (mainly macrophages), pro-inflammatory cytokines [such as tumor necrosis factor α (TNFα) and interleukin 6 (IL-6)] and inflammatory chemokines [primarily CXCL8 (interleukin 8, IL-8) and CXCL1 (GROα)] in promoting tumor cell remodeling. These inflammatory components form a common thread that is involved in regulation of the three plasticity levels: stemness/EMT, therapy resistance, and dormancy. In view of the fact that inflammatory elements are a common denominator shared by different aspects of tumor cell plasticity, it is possible that their targeting may have a critical clinical benefit for cancer patients.
000306230 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000306230 650_7 $$2Other$$acytokines/chemokines
000306230 650_7 $$2Other$$adormancy
000306230 650_7 $$2Other$$aepithelial-to-mesenchymal transition
000306230 650_7 $$2Other$$ainflammation
000306230 650_7 $$2Other$$amacrophages
000306230 650_7 $$2Other$$astemness
000306230 650_7 $$2Other$$atherapy resistance
000306230 650_7 $$2Other$$atumor cell plasticity
000306230 7001_ $$aRubinstein-Achiasaf, Linor$$b1
000306230 7001_ $$aBen-Yaakov, Hagar$$b2
000306230 7001_ $$aBen-Baruch, Adit$$b3
000306230 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2020.614468$$gVol. 10, p. 614468$$p614468$$tFrontiers in oncology$$v10$$x2234-943X$$y2020
000306230 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2022$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:01:20Z
000306230 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:01:20Z
000306230 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:01:20Z
000306230 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-08T17:01:20Z
000306230 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000306230 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000306230 980__ $$ajournal
000306230 980__ $$aI:(DE-He78)W500-20160331
000306230 980__ $$aI:(DE-He78)W510-20160331
000306230 9801_ $$aEXTERN4COORD